A number of other research firms also recently weighed in on AGN. Leerink Swann set a $217.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Thursday, March 7th. ValuEngine downgraded shares of Allergan from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. SunTrust Banks reduced their target price on shares of Allergan from $178.00 to $170.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. They noted that the move was a valuation call. Mizuho reaffirmed a “buy” rating and issued a $194.00 target price on shares of Allergan in a research report on Wednesday, April 24th. Finally, UBS Group reduced their target price on shares of Allergan from $174.00 to $173.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $178.05.
Allergan stock traded down $3.76 during mid-day trading on Monday, reaching $122.85. 2,516,330 shares of the company traded hands, compared to its average volume of 2,586,623. The company has a current ratio of 0.71, a quick ratio of 0.60 and a debt-to-equity ratio of 0.32. The company has a market cap of $41.67 billion, a P/E ratio of 7.36, a PEG ratio of 1.16 and a beta of 1.39. Allergan has a 52-week low of $120.68 and a 52-week high of $197.00.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. The business had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.55 billion. Allergan had a negative net margin of 45.94% and a positive return on equity of 8.45%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.74 EPS. Analysts predict that Allergan will post 16.68 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in AGN. Advisors Asset Management Inc. lifted its position in Allergan by 10.7% during the 4th quarter. Advisors Asset Management Inc. now owns 5,856 shares of the company’s stock worth $783,000 after buying an additional 565 shares in the last quarter. Dupont Capital Management Corp lifted its position in Allergan by 29.3% during the 4th quarter. Dupont Capital Management Corp now owns 4,283 shares of the company’s stock worth $572,000 after buying an additional 970 shares in the last quarter. Chicago Equity Partners LLC bought a new stake in Allergan during the 4th quarter worth about $355,000. Redpoint Investment Management Pty Ltd lifted its position in Allergan by 88.7% during the 4th quarter. Redpoint Investment Management Pty Ltd now owns 20,518 shares of the company’s stock worth $2,742,000 after buying an additional 9,642 shares in the last quarter. Finally, Exane Asset Management bought a new stake in Allergan during the 4th quarter worth about $77,000. Institutional investors own 80.29% of the company’s stock.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
See Also: What is a conference call?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.